NOTE

Synthesis and Cytotoxic Activity of 6-Modified Gefitinib Derivatives

  • Shen Minghui ,
  • Chen Shijie ,
  • Wang Xuewei ,
  • Gong Xianfeng ,
  • Zhang Hua
Expand
  • a Key Laboratory of Applied Organic, Heilongjiang University, Harbin 150080;
    b Sinopharm A-Think Pharmaceuticals Co., Ltd., Changchun 130012

Received date: 2015-03-22

  Revised date: 2015-04-20

  Online published: 2015-04-30

Supported by

Project supported by the Foundation of Heilongjiang Educational Committee.

Abstract

Twenty-three derivatives of gefitinib have been synthesized by etherification and esterification of 4-(3-chloro-4-fluoroanilino)-6-hydroxy-7-methoxy quinazoline, which was prepared from 2-amino-4,5-dimethoxy-benzoic acid through the reactions of cyclization, selective demethylation, acetyl protection, chlorination, substitution with 3-chloro-4-fluoro-benzenamine and deprotection, respectively. The structures of the target compounds were characterized by IR, 1H NMR, 13C NMR and HRMS spectra. All the title compounds were evaluated for cytotoxic activity against human non-small-cell-lung cancer cells lines (A549) and human hepatoma cell lines (HepG2) by methyl thiazolyl tetrazolium (MTT) method. The results showed that the cytotoxic activities of compounds 7b, 7c, 7d, 8a, 8m against human non-small-cell-lung cancer cells lines and compounds 7c, 8m against human hepatoma cell lines were comparable to those of gifitinib.

Cite this article

Shen Minghui , Chen Shijie , Wang Xuewei , Gong Xianfeng , Zhang Hua . Synthesis and Cytotoxic Activity of 6-Modified Gefitinib Derivatives[J]. Chinese Journal of Organic Chemistry, 2015 , 35(8) : 1765 -1772 . DOI: 10.6023/cjoc201503032

References

[1] Ciardiello, F.; Caputo, R.; Bianco, R.; Damiano, V.; Pomatico, G.; Placido, S. D.; Bianco, A. R.; Tortora, G. Clin. Cancer Res. 2000, 6, 2053.
[2] Moasser, M. M.; Basso, A.; Averbuch, S. D.; Rosen, N. Cancer Res. 2001, 61, 7184.
[3] Friedmann, B.; Caplin, M.; Hartley, J. A.; Hochhauser, D. Clin. Cancer Res. 2004, 10, 6476.
[4] Chang, G.-C.; Hsu, S.-L.; Tsai, J.-R.; Liang, F.-P.; Lin, S.-Y.; Sheu, G.-T.; Chen, C.-Y. Biochem. Pharmacol. 2004, 68, 1453.
[5] Lee, E. J.; Whang, J. H.; Jeon, N. K.; Kim, J. Ann. N. Y. Acad. Sci. 2007, 1095, 113.
[6] Palmer, B. D.; Trumpp, S. J. Med. Chem. 1997, 40, 1519.
[7] Trumpp, S.; Rubin, J. R. J. Med. Chem. 1998, 41, 1752.
[8] Wissner, A.; Berger, D. M.; Boschelli, D. H.; Floyed, M. B.; Greenberger, Jr. L.M.; Gruber, B. C.; Johnson, B. D.; Mamuya, N.; Nilakantan, R.; Reich, M. F.; Shen, R.; Tsou, H. R.; Upeslacis, E.; Wang, Y. F.; Wu, B.; Ye, F.; Zhang, N. J. Med. Chem. 2000, 43, 3244.
[9] Wissner, A.; Overbeek, E.; Reich, M. F.; Floyd, M. B.;Johnson, B. D.; Mamuya, N.; Rosfjord, E. C.; Discafan, C.; Davis, R.; Shi, X. Q.; Rabindran, S. K.; Gruber, B. C.; Ye, F.; Hallett, W. A.; Nilakantan, R.; Shen, R.; Wang, Y. F.; Greenberger, L. M.; Tsou, H. R. J. Med. Chem. 2003, 46, 49.
[10] Lee, J. Y.; Park, Y. K.; Seo, S. H.; So, I.-S.; Chung, H.-K.; Yang, B.-S.; Lee, S. J.; Park, H.; Lee, Y. S. Arch. Pharm. Pharm. Med. Chem. 2001, 334, 357.
[11] Lee, J.-Y.; Lee, Y.-S.; Park, H.-K.; Seo, S.-H.; Yang, B.-S.US 2003045537, 2003 [Chem. Abstr. 2003, 138, 122652c].
[12] Hou, T.-J.; Zhu, L.-L.; Chen, L.-R.; Xu, X.-J. Acta Chim. Sinica 2002, 60, 1023 (in Chinese). (侯廷军, 朱丽荔, 陈丽蓉, 徐筱杰, 化学学报, 2002, 60, 1023.)
[13] Kobayashi, S.; Boggon, T. J.; Dayaram, T.; Janne, P. A.; Kocher, O.; Meyerson, M.; Johnson, B. E.; Eck, M. J.; Tenen, D. G.; Halmos, B. N. Engl. J. Med. 2005, 352, 786.
[14] Gibson, K. H.; Grundy, W.; Godfrey, A. A.; Woodburn, J. R.; Ashton, S. E.; Curry, B. J.; Scarlett, L.; Barker, A. J.; Brown, D. S. Bioorg. Med. Chem. Lett. 1997, 7, 2723.
[15] Gibson, K. H. WO 9633980, 1996 [Chem. Abstr. 1996, 126, 47235].
[16] Du, P.; Pan, C.-Y.; Peng D.-M. Chin. J. New Drugs 2006, 21(15), 1849 (in Chinese). (杜鹏, 潘春跃, 彭东明, 中国药学杂志, 2006, 21(15), 1849.)

Outlines

/

〈 〉